Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 20/20 | 1.00 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.71 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.68 |
| ▸ | BPTF | Q12830 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17916735 | 1.00 | KAT2B (1.00) | KAT2BKAT2ABRD9BPTF | |
| SCHEMBL17916734 | 1.00 | KAT2B (1.00) | KAT2BKAT2ABRD9BPTF | |
| SCHEMBL17916739 | 1.00 | KAT2B (1.00) | KAT2BKAT2ABRD9BPTF | |
| SCHEMBL20841479 | 1.00 | KAT2B (1.00) | KAT2BKAT2ABRD9BPTF | |
| SCHEMBL17916737 | 1.00 | KAT2B (1.00) | KAT2BKAT2ABRD9BPTF | |
| SCHEMBL17916732 | 0.83 | KAT2B (1.00) | KAT2BKAT2ABRD9BPTF | |
| SCHEMBL17916726 | 0.83 | KAT2B (1.00) | KAT2BKAT2ABRD9BPTF | |
| SCHEMBL17916724 | 0.83 | KAT2B (1.00) | KAT2BKAT2ABRD9BPTF | |
| SCHEMBL17916629 | 0.82 | KAT2B (1.00) | KAT2BBPTF | |
| SCHEMBL23682875 | 0.81 | KAT2B (1.00) | KAT2BKAT2ABRD9BPTF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10239861-B2 | Therapeutic compounds and uses thereof | GENETECH, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| EP-3242874-B1 | PYRIDAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | GENENTECH INC (US) | 2018-10-31 | — | — | EP | disclosed |
| US-20180037566-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-02-08 | — | — | US | disclosed |
| US-20180037566-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-02-08 | — | — | US | disclosed |
| WO-2016112298-A1 | PYRIDAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2016-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10239861-B2 | Therapeutic compounds and uses thereof | HDAC10, HDAC6, HDAC11 | KAT2B 103/4885KAT2A 152/4885BRD9 2896/4885 |
| US-20180037566-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | HDAC10, HDAC6, HDAC11 | KAT2B 103/4885KAT2A 152/4885BRD9 2896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.